Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (21-30 of 193) with videos related to

Pageof 20
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 30, 2005
Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testingDennis A Smith, R Scott Obach
Current Protocols in Toxicology|October 10, 2012
Measurement of in vitro cytochrome P450 2B6 activityRobert L Walsky, R Scott Obach
Journal of Clinical Psychopharmacology|November 12, 2005
Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone: an in vitro studyR Scott Obach, Robert L Walsky
Environmental and Molecular Mutagenesis|July 16, 2008
Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessmentR Scott Obach, Krista L Dobo
Bioanalysis|November 19, 2010
Metabolites: have we MIST out the importance of structure and physicochemistry?Dennis A Smith, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2003
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactionsJeannine M Margolis, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 8, 2007
A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6Robert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2004
Validated assays for human cytochrome P450 activitiesRobert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 19, 2018
Emerging Models of Drug Metabolism, Transporters, and ToxicityAarti Sawant-Basak, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 19, 2010
Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokineticsR Scott Obach, Tim F Ryder
Pageof 20

Showing results (21-30 of 193) with videos related to

Sort By:
Pageof 20
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 30, 2005
Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testingDennis A Smith, R Scott Obach
Current Protocols in Toxicology|October 10, 2012
Measurement of in vitro cytochrome P450 2B6 activityRobert L Walsky, R Scott Obach
Journal of Clinical Psychopharmacology|November 12, 2005
Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone: an in vitro studyR Scott Obach, Robert L Walsky
Environmental and Molecular Mutagenesis|July 16, 2008
Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessmentR Scott Obach, Krista L Dobo
Bioanalysis|November 19, 2010
Metabolites: have we MIST out the importance of structure and physicochemistry?Dennis A Smith, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2003
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactionsJeannine M Margolis, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 8, 2007
A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6Robert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2004
Validated assays for human cytochrome P450 activitiesRobert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 19, 2018
Emerging Models of Drug Metabolism, Transporters, and ToxicityAarti Sawant-Basak, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 19, 2010
Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokineticsR Scott Obach, Tim F Ryder
Pageof 20